GAMCO Investors’s Alexion Pharmaceuticals ALXN Stock Holding History

GAMCO Investors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-15,891	Closed	-$2.92M	–	958
2021 Q2	$2.92M	Sell	15,891 -1,925	-11%	-$330K	0.02%	454
2021 Q1	$2.72M	Buy	17,816 +10,916	+158%	+$1.69M	0.02%	453
2020 Q4	$1.08M	Buy	+6,900	New	+$887K	0.01%	599
2020 Q2	–	Sell	-9,000	Closed	-$808K	–	899
2020 Q1	$808K	Hold	9,000	–	–	0.01%	576
2019 Q4	$973K	Hold	9,000	–	–	0.01%	611
2019 Q3	$881K	Buy	9,000 +2,000	+29%	+$225K	0.01%	627
2019 Q2	$917K	Hold	7,000	–	–	0.01%	622
2019 Q1	$946K	Buy	7,000 +1,000	+17%	+$124K	0.01%	588
2018 Q4	$584K	Buy	6,000 +1,000	+20%	+$118K	﹤0.01%	618
2018 Q3	$695K	Hold	5,000	–	–	﹤0.01%	635
2018 Q2	$621K	Sell	5,000 -1,000	-17%	-$117K	﹤0.01%	654
2018 Q1	$669K	Hold	6,000	–	–	﹤0.01%	629
2017 Q4	$718K	Buy	6,000 +2,000	+50%	+$244K	﹤0.01%	625
2017 Q3	$561K	Hold	4,000	–	–	﹤0.01%	670
2017 Q2	$487K	Buy	+4,000	New	+$466K	﹤0.01%	695
2015 Q3	–	Sell	-1,415	Closed	-$256K	–	846
2015 Q2	$256K	Buy	+1,415	New	+$244K	﹤0.01%	768

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

GAMCO Investors's ALXN Position: Q3 2021 in Review

GAMCO Investors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 15,891 shares — an estimated $2.92M sold.

GAMCO Investors first reported a position in ALXN in Q2 2015 and held it in 16 quarters. The position peaked at $2.92M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

GAMCO Investors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
GAMCO Investors sold 15,891 Alexion Pharmaceuticals shares in Q3 2021, an estimated $2.92M.
GAMCO Investors first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 16 quarters.
GAMCO Investors's Alexion Pharmaceuticals position peaked at $2.92M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on GAMCO Investors's 13F filing for Q3 2021, filed 12 Nov 2021.